Trial Profile

An observational trial to assess tocilizumab in patients with rheumatoid arthritis who received tocilizumab, or anti-tumour necrosis factor alpha therapy, as their first biologic therapy, versus those who received tocilizumab as either their first or subsequent biologic therapy

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Adalimumab; Certolizumab pegol; Etanercept; Infliximab
Indications Rheumatoid arthritis
Focus Therapeutic Use

27 Jul 2015 New trial record
10 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com